Clinical outcome of 200 patients with cirrhosis type B (Child A) according to hepatitis delta virus (HDV) and hepatitis B e antigen (HBeAg) status
| Anti-HDV+/HBeAg− (n = 37) | Anti-HDV+/HBeAg+ (n = 2) | Anti-HDV−/HBeAg− (n = 116) | Anti-HDV−/HBeAg+ (n = 45) | |
| HCC | 5 (13) | 0 | 19 (16) | 3 (7) |
| Decompensation* | 12 (37) | 0 | 20 (21) | 11 (26) |
| Liver related death | 6 (16) | 0 | 23 (20) | 9 (20) |
| Cause of death | ||||
| HCC | 3 | - | 12 | 2 |
| Liver failure | 3 | - | 11 | 7 |
| Unrelated | 0 | - | 3 | 2 |
| Lost to follow up | 3 (8) | 0 | 6 (5) | 2 (4) |
| Median (range) follow up (months) | 90 (14–198) | 83 (57–109) | 79 (6–181) | 66 (4–191) |
Values are expressed as number of patients (%). *Values were calculated for 173 patients who remained tumour free.
HCC, hepatocellular carcinoma.